Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study.
10.3349/ymj.2018.59.2.287
- Author:
Jung Ran CHOI
1
;
Jang Young KIM
;
Il Hwan PARK
;
Ji Hye HUH
;
Ki Woo KIM
;
Seung Kuy CHA
;
Kyu Sang PARK
;
Joon Hyung SOHN
;
Jong Taek PARK
;
Sang Baek KOH
Author Information
1. Institute of Genomic Cohort, Yonsei University Wonju College of Medicine, Wonju, Korea. kimjang713@gmail.com
- Publication Type:Original Article
- Keywords:
Metabolic syndrome;
fibroblast growth factor 21;
biomarker;
population-based prospective study
- MeSH:
Biomarkers/blood;
Female;
Fibroblast Growth Factors/*blood;
Humans;
Male;
Metabolic Syndrome/*blood;
Middle Aged;
Multivariate Analysis;
Odds Ratio;
Prospective Studies
- From:Yonsei Medical Journal
2018;59(2):287-293
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Fibroblast growth factor 21 (FGF21) is a crucial metabolic regulator, with multiple favorable effects on glucose homeostasis and lipid metabolism. Since serum FGF21 level has been implicated as a potential marker for the early identification of metabolic syndrome (MetS), we investigated the association between serum FGF21 level and the development of MetS in a population-based prospective study. MATERIALS AND METHODS: We conducted a prospective study of 221 randomly sampled adults without MetS from a general population-based cohort study who were examined from 2005–2008 (baseline) and from 2008–2011 (follow-up). Baseline serum FGF21 levels were analyzed using enzyme-linked immunosorbent assay. RESULTS: During the average 2.8-year follow-up period, 82 participants (36.6%) developed new-onset MetS. Serum FGF21 levels were significantly higher in patients with new-onset MetS than in those without MetS (209.56±226.80 vs. 110.09±81.10, p < 0.01). In multivariate adjusted models, the odds for MetS development were greater in patients with serum FGF21 levels in the highest quartile, compared to those in the lowest quartile (3.84, 95% confidence interval: 1.59–9.28). CONCLUSION: Serum FGF21 level was an independent predictor for new-onset MetS in a population-based prospective study.
